Yuekang Pharmaceutical: Subsidiary YKYY026's clinical trial application for injection for the prevention of herpes zoster has been approved.

Yuekang Pharmaceuticals announced that its subsidiaries Beijing Yuekang KeChuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceuticals Co., Ltd. have recently obtained the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for YKYY026 injection for the prevention of herpes zoster. The company will conduct Phase I clinical trials of this product. YKYY026 injection is a mRNA vaccine developed independently by Yuekang KeChuang and Hangzhou Tianlong, encoding the varicella-zoster virus gE protein antigen, used for the prevention of herpes zoster.